Thierry Andre, MD, a professor of medical oncology at the University Pierre et Marie Curie, and Head of the Medical Oncology Department in St. Antoine Hospital, Assistance Publique Hôpitaux de Paris, discusses factors that a community oncologist should consider when choosing the right treatment for patients with metastatic colorectal cancer.
Susan M. Domchek, MD, director of the Basser Center for BRCA at Penn Medicine, discusses the role biomarkers have in the treatment of patients with breast cancer. Identifying biomarkers in patients early on, such as knowledge of estrogen receptor status, can lead to better treatment plans, Domchek says.
Fatima Cardoso, MD, medical oncologist at the Champalimaud Clinical Centre in Portugal, explains the biggest issue in treatment of male breast cancer is due to lack of education. Male patients are most commonly diagnosed in the advanced stages because of this and are commonly given the wrong treatments, says Cardoso.
Lung Cancer
Ajai Chari, MD, associate professor of medicine at the Mount Sinai School of Medicine, advises on the best way to choose treatment regimens for patients with multiple myeloma. Since 9 different drugs have been approved after many phase III trials, a community physician may be overwhelmed by this surplus of options, Chari says.
Anas Younes, MD, chief of the Lymphoma Service at Memorial Sloan Kettering Cancer Center, discusses current research for staging patients with follicular lymphoma. In order to design new clinical trials, researchers must have reliable predictors of overall survival and progression-free survival in patients.
Shaji Kumar, MD, professor of medicine in the Division of Hematology at the Mayo Clinic, discusses the effects genetic abnormalities have on patients with high-risk multiple myeloma. Recent advancements have helped to identify these abnormalities in patients.
NonDriver Metastatic Lung Large Cell Carcinoma
Joaquim Bellmunt, MD, PhD, a medical oncologist at the Bladder Cancer Center at Dana-Farber Cancer Institute, discusses the updated results of the phase III KEYNOTE-045 trial after 2 years of follow-up. These updated results confirmed the primary findings of the study, which compared pembrolizumab (Keytruda) with investigator's choice of chemotherapy in patients with recurrent, advanced urothelial carcinoma.
Marina C. Garassino, MD, medical consultant in the Medical Oncology Division, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, discusses current advancements with immunotherapy as first- and second-line treatments for patients with lung cancer.
Joshua Bauml, MD, an assistant professor at Perelman School of Medicine at the University of Pennsylvania, discusses the possibilities with using liquid biopsies in patients with lung cancer.
Kathleen Moore, MD, associate director for clinical research at the Stephenson Oklahoma Cancer Center, discusses the development of combination therapy strategies for patients with ovarian cancer.
Robert Andtbacka, MD, associate professor in the Division of Surgical Oncology, Department of Surgery at the University of Utah School of Medicine, discusses a study exploring the role of talimogene laherparapvec (T-VEC; Imlygic) in the treatment of patients with metastatic melanoma.
